Beyond The Pill市場- 世界の産業規模、シェア、動向、機会、予測、治療分野別、オファリング別、地域別、競合別、2019年～2029年

世界のBeyond The Pill市場は、2023年に2億7,814万米ドルと評価され、2029年までのCAGRは6.41%で、予測期間中に目覚ましい成長を予測しています。

Beyond The Pillの世界市場は、主に価値ベースのケアと患者中心のアプローチへのシフトによって特徴付けられる、進化するヘルスケア状況によって牽引されています。製薬会社は、デジタルヘルスツール、患者支援プログラム、個別化治療など、従来の薬物療法にとどまらない総合的なソリューションの提供にますます力を入れるようになっています。このシフトは、患者の転帰の改善、服薬アドヒアランスの向上、より良い疾病管理に対する需要の高まりが後押ししています。人工知能、ビッグデータ分析、ウェアラブルデバイスなどのテクノロジーの進歩により、製薬会社は医療従事者や患者の進化するニーズに応える革新的なbeyond-the-pillソリューションを提供できるようになっています。

市場促進要因

バリューベース・ヘルスケアへのシフト

患者中心のケアに対する需要の高まり

ヘルスケアにおける技術の進歩

主な市場課題

限定的な導入とユーザーの関与

コンプライアンスの課題

主な市場動向

予防ヘルスケアへの関心の高まり

個別化医療へのシフト

セグメント別の洞察

治療分野別の洞察

オファリング別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のBeyond The Pill市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療分野別（糖尿病、がん、心血管疾患、喘息、その他）
  • オファリング（サービス、モニタリング、支援、情報、教育）別
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米のBeyond The Pill市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療分野別
  • オファリング別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のBeyond The Pill市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療分野別
  • オファリング別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のBeyond The Pill市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療分野別
  • オファリング別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のBeyond The Pill市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療分野別
  • オファリング別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのBeyond The Pill市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療分野別
  • オファリング別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併買収（もしあれば）
• 製品上市（もしあれば）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F. Hoffmann-La Roche Ltd.（Flatiron Health, Inc.）
• Otsuka Pharmaceutical Co., Ltd.
• Amgen, Inc.
• AstraZeneca PLC
• Novartis AG
• Sanofi S.A.
• Novo Nordisk A/S
• Eli Lilly and Company
• Johnson Johnson Services Inc.
• Teva Pharmaceutical Industries Ltd.

第15章 戦略的提言

第16章 免責事項

Global Beyond The Pill Market was valued at USD 278.14 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.41% through 2029. The Global Beyond The Pill Market is primarily driven by the evolving healthcare landscape, marked by a shift towards value-based care and patient-centric approaches. Pharmaceutical companies are increasingly focusing on providing holistic solutions beyond traditional medications, including digital health tools, patient support programs, and personalized therapies. This shift is fueled by the growing demand for improved patient outcomes, enhanced medication adherence, and better disease management. Advancements in technology, such as artificial intelligence, big data analytics, and wearable devices, are enabling pharmaceutical companies to offer innovative beyond-the-pill solutions that cater to the evolving needs of healthcare providers and patients alike.

Key Market Drivers

Shift Towards Value-Based Healthcare

The Global Beyond The Pill Market is experiencing significant growth, primarily due to a paradigm shift in healthcare towards value-based care models. Traditionally, healthcare systems have predominantly focused on treating acute illnesses with medication, overlooking the broader spectrum of factors influencing patient outcomes. However, there's a mounting realization that patient well-being is influenced by multiple factors beyond the efficacy of drugs alone. Consequently, pharmaceutical companies are redirecting their focus towards developing beyond-the-pill solutions that cater to holistic patient needs. These solutions encompass various aspects such as medication adherence, lifestyle modifications, and disease management strategies. By providing comprehensive solutions that address the entire patient journey, pharmaceutical companies aspire to enhance health outcomes and curtail overall healthcare expenditure.

Rising Demand for Patient-Centric Care

The surging demand for patient-centric healthcare solutions stands out as a pivotal driver propelling the growth of the Global Beyond The Pill Market. In today's healthcare landscape, patients are increasingly empowered and well-informed, seeking personalized care that aligns with their unique needs, preferences, and circumstances. Consequently, there's a growing emphasis on beyond-the-pill offerings, which encompass a spectrum of solutions such as digital health platforms, patient support programs, and remote monitoring technologies. These offerings empower patients to actively participate in managing their health and well-being, fostering a sense of autonomy and control over their healthcare journey. In response to this evolving landscape, pharmaceutical companies are prioritizing the development of innovative solutions that prioritize ', education, and empowerment. By catering to the burgeoning demand for patient-centric care, these companies are driving growth and expansion within the Beyond The Pill Market.

Technological Advancements in Healthcare

Technological advancements are fundamental drivers propelling innovation within the Global Beyond The Pill Market. The advent of digital health technologies, encompassing wearable devices, mobile applications, and telemedicine platforms, has instigated a revolutionary shift in healthcare delivery and accessibility. Leveraging these cutting-edge technologies, pharmaceutical companies are pioneering beyond-the-pill solutions that harness real-time data, predictive analytics, and remote monitoring capabilities. This transformative approach enables companies to enhance patient outcomes and optimize treatment efficacy by delivering personalized, proactive, and preventive healthcare solutions. By embracing the power of technology, pharmaceutical firms can cater to the diverse needs of patients and healthcare providers, fostering a new era of holistic and patient-centric care within the Beyond The Pill Market.

Key Market Challenges

Limited Adoption and User Engagement

Despite the potential benefits of beyond-the-pill solutions, limited adoption and user engagement present significant challenges to market growth and sustainability. Healthcare providers may exhibit reluctance to embrace new digital health technologies due to concerns about usability, workflow disruption, and perceived efficacy. Similarly, patients may be hesitant to adopt beyond-the-pill offerings if they perceive them as intrusive, complex, or unnecessary. Besides, achieving meaningful user engagement and behavior change is often challenging, particularly in the context of chronic disease management, preventive care, and lifestyle interventions. Overcoming these adoption barriers requires addressing usability concerns, enhancing user experience design, and demonstrating the value proposition of beyond-the-pill solutions through robust clinical evidence and real-world outcomes data. Also, fostering patient and provider education, training, and empowerment is essential for promoting adoption and engagement with beyond-the-pill offerings, thereby driving market uptake and scalability.

Compliance Challenges

The Global Beyond The Pill Market faces significant compliance challenges that impede innovation and market expansion. Developing and commercializing beyond-the-pill solutions often involves navigating complex regulatory frameworks and obtaining approval from multiple regulatory agencies. Unlike traditional pharmaceutical products, which are subject to well-established regulatory pathways, beyond-the-pill offerings such as digital health platforms, mobile apps, and telemedicine services may fall into regulatory grey areas or require novel regulatory approaches. Achieving compliance with diverse regulatory requirements across different jurisdictions poses a formidable challenge for companies operating in the global market. In addition, evolving regulatory standards and guidelines for digital health technologies further complicate the regulatory landscape, leading to uncertainty and delays in product development and market entry.

Key Market Trends

Growing Focus on Preventive Healthcare

The paradigm of healthcare is shifting towards preventive measures to enhance population health and alleviate the burden of chronic diseases. In this context, beyond-the-pill solutions emerge as indispensable tools supporting preventive healthcare initiatives. These solutions are designed to foster healthy behaviors, facilitate early disease detection, and enable proactive management of risk factors. Pharmaceutical companies are at the forefront of developing innovative beyond-the-pill offerings tailored to preventive interventions. These may include wellness programs, genetic testing services, and lifestyle coaching platforms. By empowering individuals to take proactive measures in safeguarding their health and well-being, these solutions not only contribute to healthcare cost savings but also yield tangible improvements in population health outcomes.

Shift Towards Personalized Medicine

The Global Beyond The Pill Market is experiencing a surge in demand propelled by the transition towards personalized medicine. This paradigm shift in healthcare delivery emphasizes the importance of tailoring treatment approaches to individual patient characteristics, genetics, and preferences. Beyond-the-pill solutions, including pharmacogenomic testing, companion diagnostics, and personalized treatment algorithms, play a pivotal role in enabling healthcare providers to customize treatment plans according to the specific needs and genetic makeup of each patient. By embracing this personalized approach, healthcare providers can enhance treatment outcomes, mitigate adverse effects, and ultimately improve patient satisfaction. In response to this growing trend, pharmaceutical companies are increasingly investing in the development of beyond-the-pill solutions that support personalized medicine initiatives, thus driving both market growth and innovation in this transformative space.

Segmental Insights

Therapeutic Area Insights

Based on the therapeutic area, oncology as a dominant force in the global beyond the pill market, is fuelled by the intricate nature of cancer, which demands multifaceted and personalized treatment strategies. The complexity and heterogeneity of cancer underscore the need for innovative beyond-the-pill solutions, as traditional drug treatments alone may not suffice. In response, pharmaceutical companies have developed a diverse array of oncology-focused interventions beyond medications. These encompass patient support programs providing emotional and practical assistance, remote monitoring technologies enabling real-time patient data collection, and precision medicine initiatives tailoring treatments to individual tumor characteristics. Secondarily, the escalating global cancer burden, alongside advancements in targeted therapies and immunotherapies, accentuates the significance of holistic patient care beyond pharmacological interventions. Thus, pharmaceutical entities are increasingly allocating resources to oncology-focused beyond-the-pill solutions to elevate patient outcomes, foster treatment adherence, and optimize healthcare delivery within the oncological landscape.

Offerings Insights

Based on the offerings segment, monitoring emerges as a dominant force, revolutionizing patient care and management. Monitoring encompasses a wide range of activities aimed at continuously observing and tracking various health parameters, vital signs, and disease progression in patients. This proactive approach allows healthcare providers to gather real-time data, assess patient health remotely, and intervene promptly when necessary. Monitoring services include wearable devices, remote patient monitoring systems, telemedicine platforms, and mobile health applications, enabling patients to monitor their health status conveniently from home or while on the go. These monitoring tools provide valuable insights into patients' conditions, facilitate early detection of health issues, and support timely interventions, thereby improving health outcomes and reducing healthcare costs. Likewise, the integration of advanced technologies such as artificial intelligence (AI) and machine learning enhances the accuracy and efficiency of monitoring solutions, enabling predictive analytics and personalized health recommendations. As healthcare continues to evolve towards value-based care models and patient-centered approaches, the role of Monitoring services becomes increasingly crucial in ensuring continuous, proactive, and personalized healthcare delivery. Thus, Monitoring emerges as the dominant category among Services, Monitoring, Assistance, Information, and Education, driving innovation and transformation in the healthcare industry.

Regional Insights

North America stands out as the leading region in the Global Beyond The Pill Market. This dominance is attributed to several key factors. North America boasts a mature and highly developed healthcare ecosystem, comprising advanced healthcare facilities, research institutions, and pharmaceutical companies at the forefront of innovation. The region's strong emphasis on patient-centric care and value-based healthcare models has spurred the adoption of beyond-the-pill solutions aimed at improving patient outcomes and reducing healthcare costs.

North America is home to a large population of tech-savvy consumers who are receptive to digital health technologies and remote monitoring solutions. The widespread adoption of wearable devices, mobile health apps, and telemedicine platforms has created a conducive environment for the growth of the Beyond The Pill Market in the region. Plus, favorable regulatory policies and incentives provided by government agencies and healthcare authorities support the development and commercialization of beyond-the-pill offerings.

Key Market Players

F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)

Otsuka Pharmaceutical Co., Ltd.

Amgen, Inc.

AstraZeneca PLC

Novartis AG

Sanofi S.A.

Novo Nordisk A/S

Eli Lilly and Company

Johnson Johnson Services Inc.

Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Beyond The Pill Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beyond The Pill Market,By Therapeutic Area:

• Diabetes
• Oncology
• Cardiovascular Diseases
• Asthma
• Others

Beyond The Pill Market,By Offerings:

• Services
• Monitoring
• Assistance
• Information
• Education

Beyond The Pill Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Beyond The Pill Market.

Available Customizations:

Global Beyond The Pill marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Beyond The Pill Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, Others)
  • 5.2.2.By Offerings (Services, Monitoring, Assistance, Information, Education),
  • 5.2.3.By Region
  • 5.2.4.By Company (2023)
• 5.3.Market Map

6.North America Beyond The Pill Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.ByTherapeutic Area
  • 6.2.2.By Offerings
  • 6.2.3.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Beyond The Pill Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Therapeutic Area
      • 6.3.1.2.2.By Offerings
  • 6.3.2.Canada Beyond The Pill Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Therapeutic Area
      • 6.3.2.2.2.By Offerings
  • 6.3.3.Mexico Beyond The Pill Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Therapeutic Area
      • 6.3.3.2.2.By Offerings

7.Europe Beyond The Pill Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Therapeutic Area
  • 7.2.2.By Offerings
  • 7.2.3.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany Beyond The Pill Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Therapeutic Area
      • 7.3.1.2.2.By Offerings
  • 7.3.2.United Kingdom Beyond The Pill Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Therapeutic Area
      • 7.3.2.2.2.By Offerings
  • 7.3.3.Italy Beyond The Pill Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Therapeutic Area
      • 7.3.3.2.2.By Offerings
  • 7.3.4.France Beyond The Pill Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Therapeutic Area
      • 7.3.4.2.2.By Offerings
  • 7.3.5.Spain Beyond The Pill Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Therapeutic Area
      • 7.3.5.2.2.By Offerings

8.Asia-Pacific Beyond The Pill Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Therapeutic Area
  • 8.2.2.By Offerings
  • 8.2.3.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Beyond The Pill Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Therapeutic Area
      • 8.3.1.2.2.By Offerings
  • 8.3.2.India Beyond The Pill Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Therapeutic Area
      • 8.3.2.2.2.By Offerings
  • 8.3.3.Japan Beyond The Pill Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Therapeutic Area
      • 8.3.3.2.2.By Offerings
  • 8.3.4.South Korea Beyond The Pill Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Therapeutic Area
      • 8.3.4.2.2.By Offerings
  • 8.3.5.Australia Beyond The Pill Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Therapeutic Area
      • 8.3.5.2.2.By Offerings

9.South America Beyond The Pill Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Therapeutic Area
  • 9.2.2.By Offerings
  • 9.2.3.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Beyond The Pill Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Therapeutic Area
      • 9.3.1.2.2.By Offerings
  • 9.3.2.Argentina Beyond The Pill Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Therapeutic Area
      • 9.3.2.2.2.By Offerings
  • 9.3.3.Colombia Beyond The Pill Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Therapeutic Area
      • 9.3.3.2.2.By Offerings

10.Middle East and Africa Beyond The Pill Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Therapeutic Area
  • 10.2.2.By Offerings
  • 10.2.3.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Beyond The Pill Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Therapeutic Area
      • 10.3.1.2.2.By Offerings
  • 10.3.2.Saudi Arabia Beyond The Pill Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Therapeutic Area
      • 10.3.2.2.2.By Offerings
  • 10.3.3.UAE Beyond The Pill Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Therapeutic Area
      • 10.3.3.2.2.By Offerings

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Merger Acquisition (If Any)
• 12.2.Product Launches (If Any)
• 12.3.Recent Developments

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Products

14.Competitive Landscape

• 14.1.F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (As Reported)
  • 14.1.5.Recent Developments
  • 14.1.6.Key Personnel Details
  • 14.1.7.SWOT Analysis
• 14.2.Otsuka Pharmaceutical Co., Ltd.
• 14.3.Amgen, Inc.
• 14.4.AstraZeneca PLC
• 14.5.Novartis AG
• 14.6.Sanofi S.A.
• 14.7.Novo Nordisk A/S
• 14.8.Eli Lilly and Company
• 14.9.Johnson Johnson Services Inc.
• 14.10.Teva Pharmaceutical Industries Ltd.

15.Strategic Recommendations

16.About Us Disclaimer